Irinotecan Hydrochloride

• Irinotecan Hydrochloride is a chemotherapy agent that targets topoisomerase I, an enzyme essential for DNA replication in cancer cells.
• It is primarily used in the treatment of metastatic colorectal cancer, often in combination with other drugs.
• The drug works by causing DNA damage, which leads to programmed cell death in rapidly dividing cancer cells.
• Dosage is highly individualized and administered intravenously under strict medical supervision.
• Common side effects include severe diarrhea and myelosuppression, which require careful monitoring and management.

What is Irinotecan Hydrochloride?

Irinotecan Hydrochloride is a chemotherapy medication used in the treatment of various cancers. It is a semisynthetic analog of camptothecin, a natural alkaloid, and functions as a potent antineoplastic agent. This drug is administered intravenously and is designed to interfere with the growth of cancer cells, ultimately leading to their destruction. Its application is typically reserved for specific types of advanced or metastatic cancers, often when other treatments have been unsuccessful or as part of a multi-drug regimen.

Mechanism of Action and Therapeutic Uses

The Irinotecan Hydrochloride mechanism of action involves its active metabolite, SN-38, which inhibits topoisomerase I. Topoisomerase I is an enzyme crucial for DNA replication, transcription, and repair in both healthy and cancerous cells. By binding to and stabilizing the cleavable complex between topoisomerase I and DNA, SN-38 prevents the re-ligation of DNA single-strand breaks. This leads to an accumulation of DNA damage, particularly during the S-phase of the cell cycle, ultimately triggering apoptosis (programmed cell death) in rapidly dividing cancer cells. This targeted disruption of DNA synthesis makes Irinotecan Hydrochloride an effective agent against various malignancies.

Irinotecan Hydrochloride uses primarily include the treatment of metastatic colorectal cancer, where it is often used in combination with fluorouracil and leucovorin (the FOLFIRI regimen). Beyond colorectal cancer, it is also indicated for other specific cancers. The therapeutic applications are determined by an oncologist based on the type and stage of cancer, as well as the patient’s overall health.

Key therapeutic applications for Irinotecan Hydrochloride include:

• Metastatic colorectal cancer (first-line or second-line treatment)
• Pancreatic cancer (often in combination with other agents)
• Small cell lung cancer (in certain regimens)
• Other solid tumors, sometimes in investigational settings

Dosage Information and Potential Side Effects

Irinotecan Hydrochloride dosage information is highly individualized and determined by a qualified oncologist. The dosage regimen depends on several factors, including the specific type of cancer being treated, the patient’s body surface area, their overall health, and whether the drug is administered as a single agent or in combination with other chemotherapy drugs. It is typically given intravenously over a period, often on a weekly or bi-weekly schedule. Close monitoring of blood counts and liver function is essential throughout the treatment course to adjust doses as needed and manage potential toxicities effectively.

Like most chemotherapy agents, Irinotecan Hydrochloride side effects can be significant due to its impact on rapidly dividing cells, including healthy ones. Patients must be closely monitored for adverse reactions. The most common and clinically significant side effects include severe diarrhea, which can be early-onset (cholinergic syndrome) or delayed, and myelosuppression, particularly neutropenia (a decrease in white blood cells), which increases the risk of infection. Other frequent side effects are nausea, vomiting, fatigue, hair loss (alopecia), and abdominal cramping.

Management of these side effects is crucial for patient safety and treatment adherence. For instance, severe diarrhea often requires aggressive hydration and anti-diarrheal medications like loperamide. Myelosuppression necessitates regular blood tests and may require dose reductions or growth factor support to prevent serious infections. Patients are educated on recognizing and reporting side effects promptly to their healthcare team.